Invests in
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Education
Lists including Kuang
Work Experience
2024
Vice President
2024
- Focused on company creations in the therapeutics space (pre-Seed, Seed financings) and occasional direct Series A-B investments - Drive strategic decision making in near-clinic and clinical-stage companies in the portfolio
2025
Board Observer
2025
2025
Board Member
2025
2024
Board Observer
2024
2024
Board Observer
2024
2019 - 2023
Analyst/Associate
2019 - 2023
Focused on equity investments in clinical-stage pharmaceutical and medical devices companies in the CrossOver Fund. Led due diligence on: - Mainstay Medical $108m Series A in 2021 - CytoImmune $27m Series A in 2021 - Artios Pharma $153m Series C in 2021 - Amolyt Pharma $138m Series C in 2023 (acquired by AstraZeneca for $1.05b in 2024)
2017 - 2019
Clinical Research Fellow - Hematology/Oncology
2017 - 2019
2014 - 2016
Microbiologist
2014 - 2016
2011 - 2011
Summer Intern - Beauty & Grooming
2011 - 2011